@article{SchaeferBauerDonhauseretal.2017,
  author    = {Sch{\"a}fer, Kristina and Bauer, Boris and Donhauser, Julian and Kerstan, Andreas and Hamm, Henning},
  title     = {Becker Naevus Syndrome of the Lower Body: A New Case and Review of the Literature},
  series = {Acta Dermato-Venereologica},
  volume    = {97},
  journal   = {Acta Dermato-Venereologica},
  number    = {4},
  doi       = {10.2340/00015555-2589},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-171057},
  pages     = {499-504},
  year      = {2017},
  abstract  = {Becker naevus syndrome is a rare epidermal naevus syndrome defined by the co-occurrence of a Becker naevus with various cutaneous, muscular and skeletal anomalies. In the majority of cases, abnormalities exclusively consist of ipsilateral hypoplasia of the breast, areola and/or nipple in addition to the naevus. Here, we report on a 42-year-old woman with an extensive Becker naevus reaching from the left buttock to the left calf verified on histological examination. In addition, there was marked hypoplasia of the fatty tissue of the left thigh confirmed by magnetic resonance imaging in contrast to hyperplasia of the fatty tissue of the left gluteal area. Underlying muscles and bones were not affected. There was no difference in leg lengths. In addition, we review and discuss the features of Becker naevus syndrome with emphasis on 10 reported cases with involvement of the lower body.},
  language  = {en}
}
@article{StoevesandtHospKerstanetal.2017,
  author    = {Stoevesandt, Johanna and Hosp, Christine and Kerstan, Andreas and Trautmann, Axel},
  title     = {Safety of 100 µg venom immunotherapy rush protocols in children compared to adults},
  series = {Allergy, Asthma \& Clinical Immunology},
  volume    = {13},
  journal   = {Allergy, Asthma \& Clinical Immunology},
  number    = {32},
  doi       = {10.1186/s13223-017-0204-y},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-157830},
  year      = {2017},
  abstract  = {Background: There is a paucity of studies examining the safety of venom immunotherapy (VIT) in children. We aimed to assess the incidence of anaphylactic side effects during rush VIT in a cohort of pediatric patients and adult controls. Methods: 72 consecutive cycles of VIT-buildup in 71 children/adolescents aged 7-17 years were retrospectively evaluated and compared to an adult control group (n = 981) with regard to baseline parameters (sex, causative venom, severity of index sting reaction, results of allergy testing, comorbidities) and the incidence of anaphylactic adverse reactions. Results: Compared to adults, severe index sting-induced anaphylaxis was significantly less common in children (P = .001). Children were more likely to suffer from bee venom allergy (P < .001) and showed higher levels of bee venom-specific IgE (P = .013), but lower serum tryptase concentrations (P = .014). The overall rate of VIT-induced anaphylactic reactions was higher in children than in adults (6.9\% vs 2.5\%, P = .046 by univariate analysis). In the final binary logistic regression model, however, only bee VIT (P = .039; odds ratio 2.25; confidence interval 1.04-4.87) and 5-day compared to 3-day buildup protocols (P = .011; odds ratio 2.64; confidence interval 1.25-5.57) were associated with an increased risk of treatment-induced anaphylaxis. All pediatric patients finally reached and tolerated the target maintenance dose of 100 µg. Conclusions: The higher anaphylactic reaction rate observed in pediatric patients may be attributed to a greater prevalence of bee venom allergy. VIT-induced anaphylaxis in children is usually mild and does not affect further updosing and maintenance of VIT.},
  language  = {en}
}